Sökning: WFRF:(O'Connell Rachel L.) >
Measuring what matt...
Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer
-
- King, Madeleine T. (författare)
- Univ Sydney, Australia; Univ Sydney, Australia
-
- Stockler, Martin R. (författare)
- ANZGOG, Australia
-
- OConnell, Rachel L. (författare)
- Univ Sydney, Australia
-
visa fler...
-
- Buizen, Luke (författare)
- Univ Sydney, Australia
-
- Joly, Florence (författare)
- Ctr Francois Baclesse, France
-
- Lanceley, Anne (författare)
- UCL, England
-
- Hilpert, Felix (författare)
- Krankenhaus Jerusalem Hamburg, Germany
-
- Okamoto, Aikou (författare)
- Jikei Univ, Japan
-
- Aotani, Eriko (författare)
- Kanagawa Acad Sci and Technol, Japan
-
- Bryce, Jane (författare)
- IRCCS, Italy
-
- Donnellan, Paul (författare)
- Galway Univ Hosp, Ireland
-
- Oza, Amit (författare)
- Univ Toronto, Canada
-
- Åvall-Lundqvist, Elisabeth, 1957- (författare)
- Karolinska Institutet,Linköpings universitet,Avdelningen för Kirurgi, Ortopedi och Onkologi,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US,Karolinska Inst, Sweden
-
- Berek, Jonathan S. (författare)
- Stanford Comprehens Canc Inst, CA USA
-
- Sehouli, Jalid (författare)
- AGO Study Grp, Germany,Univ Sydney, Australia
-
- Feeney, Amanda (författare)
- UCL, England
-
- Berton-Rigaud, Dominique (författare)
- GINECO, France
-
- Costa, Daniel S. J. (författare)
- Univ Sydney, Australia
-
- Friedlander, Michael L. (författare)
- ANZGOG, Australia
-
visa färre...
-
(creator_code:org_t)
- 2017-12-16
- 2018
- Engelska.
-
Ingår i: Quality of Life Research. - : SPRINGER. - 0962-9343 .- 1573-2649. ; 27:1, s. 59-74
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM), the Measure of Ovarian Symptoms and Treatment concerns (MOST), developed in GCIG-SBS Stage 1 (MOSTv1, 35 items), and document recurrent ovarian cancer (ROC) symptom burden and benefit. GCIG-SBS Stage 2 recruited patients with platinum-resistant/refractory ROC (PRR-ROC) or potentially platinum-sensitive ROC with aeamp;lt;yenamp;gt; 3 lines of prior chemotherapy (PPS-ROC aeamp;lt;yenamp;gt; 3). Patients completed MOSTv1, QLQ-C30, QLQ-OV28, and FACT-O/FOSI at baseline and before cycle 3 of chemotherapy (pre-C3), and global assessments of change (MOST-Change) pre-C3. Clinicians rated patients cancer-related symptoms, performance status, and adverse events. Convergent and divergent validity (Spearmans correlations), discriminative validity (effect sizes between groups classified by clinician-rated characteristics), and responsiveness (paired t tests in patients expected to experience clinically meaningful change) were assessed. Of 948 recruits, 903 completed PROMs at baseline and 685 pre-C3. Baseline symptom burden was substantial for PRR-ROC and PPS-ROC aeamp;lt;yenamp;gt; 3. MOSTv2 has 24 items and five multi-item scales: abdominal symptoms (MOST-Abdo), disease or treatment-related symptoms (MOST-DorT), chemotherapy-related symptoms (MOST-Chemo), psychological symptoms (MOST-Psych), and MOST-Well-being. Correlations confirmed concurrent and divergent validity. Discriminative validity was confirmed by effect sizes that conformed with a priori hypotheses. MOST-Abdo was responsive to improvements in abdominal symptoms and MOST-Chemo detected the adverse effects of chemotherapy. The MOSTv2 validly quantifies patient-reported symptom burden, adverse effects, and symptom benefit in ROC, and as such is fit-for-purpose for clinical trials of palliative chemotherapy in ROC. Further research is required to assess test-retest reliability.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- Ovarian cancer; Recurrent ovarian cancer; Platinum sensitive; Platinum resistant; Platinum refractory; Symptom burden; Symptom benefit; Magnitude of clinical benefit; Net health benefit; Patient-reported outcome; PRO; Patient-reported outcome measure; PROM; Quality of life; QOL; Health-related quality of life; HRQOL; HRQL
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
King, Madeleine ...
-
Stockler, Martin ...
-
OConnell, Rachel ...
-
Buizen, Luke
-
Joly, Florence
-
Lanceley, Anne
-
visa fler...
-
Hilpert, Felix
-
Okamoto, Aikou
-
Aotani, Eriko
-
Bryce, Jane
-
Donnellan, Paul
-
Oza, Amit
-
Åvall-Lundqvist, ...
-
Berek, Jonathan ...
-
Sehouli, Jalid
-
Feeney, Amanda
-
Berton-Rigaud, D ...
-
Costa, Daniel S. ...
-
Friedlander, Mic ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Quality of Life ...
- Av lärosätet
-
Linköpings universitet
-
Karolinska Institutet